The 6th Annual Phase I Clinical Trials Conference

14th – 17th June, London

Richmond Pharmacology in conjunction with IIR Life Sciences

The event

The 6th Annual Phase I Clinical Trials Conference is the only industry-focused European meeting dealing with regulatory, operational and technological developments in the international Phase I environment.

As well as an essential applied regulatory update, the meeting will showcase novel technologies for expediting Phase I trials and explore related areas, including cardiovascular safety assessment, imaging and biomarkers.

Richmond Pharmacology

As part of the conference, Dr Jörg Täubel will explore the new paradigm of Phase I Patient Studies.

“Early Phase Trials Integration – redefining the boundaries”

The speaker will explore an integrated approach to clinical trials and the advantages of the recently implemented EU Clinical Trials Directive by reaching patient groups from the onset of a compound's clinical development.

The presentation will consider crucial elements required to deliver a Phase I patient study, including in-patient facilities and access to consultants, patient populations, and specialist services such as biomarker analysis, proteomics and genomics, providing a one centre solution to early phase studies.

Day 2: 15th June 2005, 10:20am, Stream B

Booking:

For more information on attending the event as guests of Richmond and receiving a 25% discount on the ticket price, please contact Charlotte Gowling on 020 8879 7111 or email c.gowling@richmondpharmacology.com.

Key presentations include:

Dr Rashmi Shah
Formerly European Support Unit, UK Medicines & Healthcare Products Regulatory Agency (MHRA)/EMEA
Dr Harsukh Parmar
Director, Global Experimental Medicine, AstraZeneca R&D
Dr Giles Campion
European Head of Exploratory Clinical Development, Novartis
Professor Graham McClelland
Global Head, Clinical Pharmacology, Roche Products
Dr Roy Bullingham
President, Daiichi Medical Research Inc

Among topics to be discussed:

  • Minimum criteria for use of biomarkers in humans: An EU perspective
  • Drug-induced QT interval prolongation: EU regulatory perspectives on ICH Step 2
  • The move to patients: when, whys and hows of exploratory development
  • End Early drug interaction studies: a regulator's perspective on various approaches

Conference details

Venue

London Hilton Paddington
146 Praed Street
London
W2 1EE

Tel: +44 (0) 20 7850 0500
Fax: +44 (0) 20 7850 0500



In this section